Page last updated: 2024-10-16

carnitine and Osteoarthritis, Hip

carnitine has been researched along with Osteoarthritis, Hip in 2 studies

Osteoarthritis, Hip: Noninflammatory degenerative disease of the hip joint which usually appears in late middle or old age. It is characterized by growth or maturational disturbances in the femoral neck and head, as well as acetabular dysplasia. A dominant symptom is pain on weight-bearing or motion.

Research Excerpts

ExcerptRelevanceReference
"Our data suggest three possible clinically actionable endotypes in primary OA: muscle weakness, arginine deficit and low inflammatory OA."4.02Endotypes of primary osteoarthritis identified by plasma metabolomics analysis. ( Furey, A; Liu, M; Rahman, P; Randell, EW; Sun, G; Werdyani, S; Zhai, G; Zhang, H, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Werdyani, S1
Liu, M1
Zhang, H1
Sun, G1
Furey, A1
Randell, EW1
Rahman, P1
Zhai, G1
Tootsi, K1
Kals, J1
Zilmer, M1
Paapstel, K1
Ottas, A1
Märtson, A1

Other Studies

2 other studies available for carnitine and Osteoarthritis, Hip

ArticleYear
Endotypes of primary osteoarthritis identified by plasma metabolomics analysis.
    Rheumatology (Oxford, England), 2021, 06-18, Volume: 60, Issue:6

    Topics: Aged; Arginine; Body Mass Index; Carnitine; Case-Control Studies; Coronary Disease; Diabetes Mellitu

2021
Medium- and long-chain acylcarnitines are associated with osteoarthritis severity and arterial stiffness in end-stage osteoarthritis patients: a case-control study.
    International journal of rheumatic diseases, 2018, Volume: 21, Issue:6

    Topics: Aged; Biomarkers; Carnitine; Case-Control Studies; Down-Regulation; Female; Humans; Male; Metabolomi

2018